CoChat

The predictive and prognostic role of radiologically defined sarcopenia in head and neck cancer: a systematic review and multi-level meta-analysis

van Heusden, Hugo C., van Beers, Maartje A., Schaeffers, Anouk W. M. A., Swartz, Emma, Swartz, Justin E., de Bree, Remco · 2025 · British Journal of Cancer
Cited by 25

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Radiologically defined sarcopenia (RS), defined as a lack of skeletal muscle mass (SMM) measured on cross-sectional CT or MR imaging, is increasingly recognized as a significant prognostic determinant in head and neck cancer (HNC). A systematic literature search of Embase and Medline was performed to identify studies investigating the impact of pre-treatment sarcopenia on the prognosis of HNC patients. All available survival and other treatment-related outcomes were extracted and analyzed in a multi-level meta-analysis. Sixty-three studies comprising data from 14,804 patients were analyzed. The overall estimated log OR was 0.644 (95% CI = 0.505–0.783, p < 0.001), suggesting that patients with RS have a higher risk of worse outcomes. In 43 studies there was a significant effect of sarcopenia on survival, with a log OR of 0.808 (95% CI = 0.509–1.107, p < 0.001). In 15 studies RS was shown to be a risk factor for treatment-related complications (log OR = 0.669, 95% CI = 0.441–0.897, p < 0.001). We conclude that pre-treatment radiologically defined sarcopenia is a robust prognostic and predictive factor in HNC patients and is associated with worse survival and increased risk of treatment-related complications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41416-025-03049-7

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 100

  1. Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233:780–6. https://doi.org/10.1038/s41415-022-5166-x. · DOI · Paper page
  2. Chow LQM. Head and neck cancer. N Engl J Med. 2020;382:60–72. https://doi.org/10.1056/nejmra1715715. · DOI · Paper page
  3. Alshadwi A, Nadershah M, Carlson ER, Young LS, Burke PA, Daley BJ. Nutritional considerations for head and neck cancer patients: a review of the literature. J Oral Maxillofac Surg. 2013;71:1853–60. https://doi.org/10.1016/j.joms.2013.04.028. · DOI · Paper page
  4. Zwart AT, Van Der Hoorn A, Van Ooijen PMA, Steenbakkers RJHM, De Bock GH, Halmos GB. CT‐measured skeletal muscle mass used to assess frailty in patients with head and neck cancer. J Cachexia Sarcopenia Muscle. 2019;10:1060–9. https://doi.org/10.1002/jcsm.12443. · DOI
  5. Pressoir M, Desné S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102:966–71. https://doi.org/10.1038/sj.bjc.6605578. · DOI · Paper page
  6. Givens DJ, Karnell LH, Gupta AK, Clamon GH, Pagedar NA, Chang KE, et al. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otolaryngol Neck Surg. 2009;135:1209. https://doi.org/10.1001/archoto.2009.174. · DOI · Paper page
  7. Silva PB, Ramos GHA, Petterle RR, Borba VZC. Sarcopenia as an early complication of patients with head and neck cancer with dysphagia. Eur J Cancer Care. 2021;30:e13343. https://doi.org/10.1111/ecc.13343. · DOI
  8. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95. https://doi.org/10.1016/s1470-2045(10)70218-7. · DOI · Paper page
  9. Van Beers MA, Speksnijder CM, Van Gils CH, Frederix GWJ, Dankbaar JW, De Bree R. Prophylactic pectoralis major flap to compensate for increased risk of pharyngocutaneous fistula in laryngectomy patients with low skeletal muscle mass (PECTORALIS): study protocol for a randomized controlled trial. BMC Cancer. 2024;24:76. https://doi.org/10.1186/s12885-023-11773-7. · DOI
  10. Schaeffers AWMA, Devriese LA, Van Gils CH, Dankbaar JW, Voortman J, De Boer JP, et al. Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: the CISLOW-study protocol. PLOS One. 2023;18:e0294147. https://doi.org/10.1371/journal.pone.0294147. · DOI
  11. Molenaar CJL, Minnella EM, Coca-Martinez M, Ten Cate DWG, Regis M, Awasthi R, et al. Effect of multimodal prehabilitation on reducing postoperative complications and enhancing functional capacity following colorectal cancer surgery: the PREHAB randomized clinical trial. JAMA Surg. 2023;158:572. https://doi.org/10.1001/jamasurg.2023.0198. · DOI · Paper page
  12. Loewen I, Jeffery CC, Rieger J, Constantinescu G. Prehabilitation in head and neck cancer patients: a literature review. J Otolaryngol Head Neck Surg. 2021;50:2. https://doi.org/10.1186/s40463-020-00486-7. · DOI
  13. Hayden JA, Van Der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158:280. https://doi.org/10.7326/0003-4819-158-4-201302190-00009. · DOI · Paper page
  14. Geeraert L, Van Den Noortgate W, Grietens H, Onghena P. The effects of early prevention programs for families with young children at risk for physical child abuse and neglect: a meta-analysis. Child Maltreat. 2004;9:277–91. https://doi.org/10.1177/1077559504264265. · DOI · Paper page
  15. Achim V, Bash J, Mowery A, Guimaraes AR, Li R, Schindler J, et al. Prognostic indication of sarcopenia for wound complication after total laryngectomy. JAMA Otolaryngol Neck Surg. 2017;143:1159. https://doi.org/10.1001/jamaoto.2017.0547. · DOI
  16. Ahern E, Brown TE, Campbell L, Hughes BGM, Banks M, Lin CY, et al. Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment. Br J Nutr. 2023;129:406–15. https://doi.org/10.1017/s0007114522000435. · DOI
  17. Alwani MM, Jones AJ, Novinger LJ, Pittelkow E, Bonetto A, Sim MW, et al. Impact of sarcopenia on outcomes of autologous head and neck free tissue reconstruction. J Reconstr Microsurg. 2020;36:369–78. https://doi.org/10.1055/s-0040-1701696. · DOI
  18. Ansari E, Chargi N, Van Gemert JTM, Van Es RJJ, Dieleman FJ, Rosenberg AJWP, et al. Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap. Oral Oncol. 2020;101:104530. https://doi.org/10.1016/j.oraloncology.2019.104530. · DOI
  19. Ansari E, Chargi N, Van Es RJJ, Dieleman FJ, Van Cann EM, De Bree R. Association of preoperative low skeletal muscle mass with postoperative complications after selective neck dissection. Int J Oral Maxillofac Surg. 2022;51:1389–93. https://doi.org/10.1016/j.ijom.2022.02.008. · DOI
  20. Arribas L, Plana M, Taberna M, Sospedra M, Vilariño N, Oliva M, et al. Predictive value of skeletal muscle mass in recurrent/metastatic head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors. Front Oncol. 2021;11:699668. https://doi.org/10.3389/fonc.2021.699668. · DOI
  21. Bardoscia L, Besutti G, Pellegrini M, Pagano M, Bonelli C, Bonelli E, et al. Impact of low skeletal muscle mass and quality on clinical outcomes in patients with head and neck cancer undergoing (chemo)radiation. Front Nutr. 2022;9:994499. https://doi.org/10.3389/fnut.2022.994499. · DOI
  22. Becker JN, Hermann R, Wichmann J, Sonnhoff M, Christiansen H, Bruns F. Low skeletal muscle mass is predictive of dose-limiting toxicities in head and neck cancer patients undergoing low-dose weekly cisplatin chemoradiotherapy. PLOS One. 2023;18:e0282015. https://doi.org/10.1371/journal.pone.0282015. · DOI
  23. Bentahila R, Giraud P, Decazes P, Kreps S, Nay P, Chatain A, et al. The impact of sarcopenia on survival and treatment tolerance in patients with head and neck cancer treated with chemoradiotherapy. Cancer Med. 2023;12:4170–83. https://doi.org/10.1002/cam4.5278. · DOI · Paper page
  24. Bonavolontà P, Improta G, Dell’Aversana Orabona G, Goglia F, Abbate V, Sorrentino A, et al. Evaluation of sarcopenia and sarcopenic obesity in patients affected by oral squamous cell carcinoma: a retrospective single-center study. J Cranio Maxillofac Surg. 2023;51:7–15. https://doi.org/10.1016/j.jcms.2023.01.014. · DOI
  25. Bril SI, Pezier TF, Tijink BM, Janssen LM, Braunius WW, De Bree R. Preoperative low skeletal muscle mass as a risk factor for pharyngocutaneous fistula and decreased overall survival in patients undergoing total laryngectomy. Head Neck. 2019;41:1745–55. https://doi.org/10.1002/hed.25638. · DOI
  26. Bril SI, Al‐Mamgani A, Chargi N, Remeijer P, Devriese LA, De Boer JP, et al. The association of pretreatment low skeletal muscle mass with chemotherapy dose‐limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high‐dose cisplatin. Head Neck. 2022;44:189–200. https://doi.org/10.1002/hed.26919. · DOI
  27. Casasayas M, García-Lorenzo J, Gómez-Ansón B, Medina V, Fernández A, Quer M, et al. Low skeletal muscle mass assessed directly from the 3rd cervical vertebra can predict pharyngocutaneous fistula risk after total laryngectomy in the male population. Eur Arch Otorhinolaryngol. 2022;279:853–63. https://doi.org/10.1007/s00405-021-07127-3. · DOI
  28. Chang S, Hsu C, Tsai Y, Chang G, Tsai M, Huang EI, et al. Prognostic value of third cervical vertebra skeletal muscle index in oral cavity cancer: a retrospective study. Laryngoscope. 2021;131:E2257–E2265. https://doi.org/10.1002/lary.29390. · DOI
  29. Chargi N, Bril SI, Emmelot-Vonk MH, De Bree R. Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. Eur Arch Otorhinolaryngol. 2019;276:1475–86. https://doi.org/10.1007/s00405-019-05361-4. · DOI
  30. Chargi N, Bril SI, Swartz JE, Wegner I, Willems SM, De Bree R. Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma. Oral Oncol. 2020;101:104519. https://doi.org/10.1016/j.oraloncology.2019.104519. · DOI
  31. Chargi N, Bashiri F, Wendrich AW, Smid EJ, De Jong PA, Huitema ADR, et al. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer. Eur Arch Otorhinolaryngol. 2022;279:3685–94. https://doi.org/10.1007/s00405-021-07229-y. · DOI
  32. Choi Y, Ahn K, Jang J, Shin N, Jung S, Kim B, et al. Prognostic value of computed tomography‐based volumetric body composition analysis in patients with head and neck cancer: Feasibility study. Head Neck. 2020;42:2614–25. https://doi.org/10.1002/hed.26310. · DOI
  33. Erul E, Guven DC, Ozbay Y, Altunbulak AY, Kahvecioglu A, Ercan F, et al. Evaluation of sarcopenia as a prognostic biomarker in locally advanced head and neck squamous cell carcinoma. Biomark Med. 2023;17:87–99. https://doi.org/10.2217/bmm-2022-0748. · DOI
  34. Findlay M, Brown C, De Abreu Lourenço R, White K, Bauer J. Sarcopenia and myosteatosis in patients undergoing curative radiotherapy for head and neck cancer: Impact on survival, treatment completion, hospital admission and cost. J Hum Nutr Diet. 2020;33:811–21. https://doi.org/10.1111/jhn.12788. · DOI
  35. Findlay M, White K, Brown C, Bauer JD. Nutritional status and skeletal muscle status in patients with head and neck cancer: impact on outcomes. J Cachexia Sarcopenia Muscle. 2021;12:2187–98. https://doi.org/10.1002/jcsm.12829. · DOI
  36. Galli A, Colombo M, Prizio C, Carrara G, Lira Luce F, Paesano PL, et al. Skeletal muscle depletion and major postoperative complications in locally-advanced head and neck cancer: a comparison between ultrasound of rectus femoris muscle and neck cross-sectional imaging. Cancers. 2022;14:347. https://doi.org/10.3390/cancers14020347. · DOI
  37. Ganju RG, Morse R, Hoover A, TenNapel M, Lominska CE. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol. 2019;137:117–24. https://doi.org/10.1016/j.radonc.2019.04.023. · DOI
  38. Grossberg AJ, Chamchod S, Fuller CD, Mohamed ASR, Heukelom J, Eichelberger H, et al. Association of body composition with survival and locoregional control of radiotherapy-treated head and neck squamous cell carcinoma. JAMA Oncol. 2016;2:782. https://doi.org/10.1001/jamaoncol.2015.6339. · DOI · Paper page
  39. Haehl E, Alvino L, Rühle A, Zou J, Fabian A, Grosu AL, et al. Sarcopenia as a prognostic marker in elderly head and neck squamous cell carcinoma patients undergoing (chemo-)radiation. Cancers. 2022;14:5536. https://doi.org/10.3390/cancers14225536. · DOI
  40. He WZ, Jiang C, Liu LL, Yin CX, Rong YM, Hu WM, et al. Association of body composition with survival and inflammatory responses in patients with non-metastatic nasopharyngeal cancer. Oral Oncol. 2020;108:104771. https://doi.org/10.1016/j.oraloncology.2020.104771. · DOI
  41. Hua X, Li WZ, Huang X, Wen W, Huang HY, Long ZQ, et al. Modeling sarcopenia to predict survival for patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy. Front Oncol. 2021;11:625534. https://doi.org/10.3389/fonc.2021.625534. · doi:10.3389/fonc.2021.625534
  42. Huang X, Ma J, Li L, Zhu X. Severe muscle loss during radical chemoradiotherapy for non‐metastatic nasopharyngeal carcinoma predicts poor survival. Cancer Med. 2019;8:6604–13. https://doi.org/10.1002/cam4.2538. · DOI
  43. Huang X, Lv LN, Zhao Y, Li L, Zhu XD. Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study. Clin Nutr. 2021;40:295–302. https://doi.org/10.1016/j.clnu.2020.05.020. · DOI · Paper page
  44. Huang CH, Lue KH, Chen PR, Hsieh TC, Chou YF. Association between sarcopenia and immediate complications and mortality in patients with oral cavity squamous cell carcinoma undergoing surgery. Cancers. 2022;14:785. https://doi.org/10.3390/cancers14030785. · DOI
  45. Huiskamp LFJ, Chargi N, Devriese LA, De Jong PA, De Bree R. The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy. Eur Arch Otorhinolaryngol. 2020;277:2847–58. https://doi.org/10.1007/s00405-020-05972-2. · DOI
  46. Jin W, Rich B, Yechieli R, Freedman L, Samuels MA, Abramowitz M, et al. A single axial slice of the sternocleidomastoids and paravertebral muscles associated with worse local progression-free survival and severe toxicity in sarcopenic head and neck cancer patients undergoing radiotherapy. Cureus. 2022;14:e22463. https://doi.org/10.7759/cureus.22463. · DOI
  47. Jones AJ, Campiti VJ, Alwani M, Novinger LJ, Tucker BJ, Bonetto A, et al. Sarcopenia is associated with blood transfusions in head and neck cancer free flap surgery. Laryngoscope Investig Otolaryngol. 2021;6:200–10. https://doi.org/10.1002/lio2.530. · DOI
  48. Jung AR, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY. Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer. Oral Oncol. 2019;95:95–9. https://doi.org/10.1016/j.oraloncology.2019.06.009. · DOI
  49. Jung AR, Roh JL, Kim JS, Kim SB, Choi SH, Nam SY, et al. Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer. Eur J Cancer. 2019;116:98–106. https://doi.org/10.1016/j.ejca.2019.05.006. · DOI
  50. Jung AhR, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY. The impact of skeletal muscle depletion on older adult patients with head and neck cancer undergoing primary surgery. J Geriatr Oncol. 2021;12:128–33. https://doi.org/10.1016/j.jgo.2020.06.009. · DOI
  51. Karsten RT, Al‐Mamgani A, Bril SI, Tjon‐A‐Joe S, Van Der Molen L, De Boer JP, et al. Sarcopenia, a strong determinant for prolonged feeding tube dependency after chemoradiotherapy for head and neck cancer. Head Neck. 2019;41:4000–8. https://doi.org/10.1002/hed.25938. · DOI
  52. Lee J, Liu S, Dai K, Huang Y, Li C, Chen JC, et al. Sarcopenia and systemic inflammation synergistically impact survival in oral cavity cancer. Laryngoscope. 2021;131:E1530–E1538. https://doi.org/10.1002/lary.29221. · DOI
  53. Lee B, Bae YJ, Jeong WJ, Kim H, Choi BS, Kim JH. Temporalis muscle thickness as an indicator of sarcopenia predicts progression-free survival in head and neck squamous cell carcinoma. Sci Rep. 2021;11:19717. https://doi.org/10.1038/s41598-021-99201-3. · DOI
  54. Lee J, Liu SH, Chen JCH, Leu YS, Liu CJ, Chen YJ. Progressive muscle loss is an independent predictor for survival in locally advanced oral cavity cancer: a longitudinal study. Radiother Oncol. 2021;158:83–9. https://doi.org/10.1016/j.radonc.2021.02.014. · doi:10.1016/j.radonc.2021.02.014
  55. Lin S, Lin Y, Kang B, Yin C, Chang K, Chi C, et al. Sarcopenia results in poor survival rates in oral cavity cancer patients. Clin Otolaryngol. 2020;45:327–33. https://doi.org/10.1111/coa.13481. · DOI
  56. Makiguchi T, Yamaguchi T, Nakamura H, Suzuki K, Harimoto N, Shirabe K, et al. Impact of skeletal muscle mass volume on surgical site infection in free flap reconstruction for oral cancer. Microsurgery. 2019;39:598–604. https://doi.org/10.1002/micr.30494. · doi:10.1002/micr.30494
  57. Mascarella MA, Patel T, Vendra V, Gardiner L, Kergoat M, Kubik MW, et al. Poor treatment tolerance in head and neck cancer patients with low muscle mass. Head Neck. 2022;44:844–50. https://doi.org/10.1002/hed.26978. · doi:10.1002/hed.26978
  58. Mascarella MA, Gardiner L, Patel T, Vendra V, Khan N, Kergoat M, et al. Cervical paraspinal skeletal muscle index outperforms frailty indices to predict postoperative adverse events in operable head and neck cancer with microvascular reconstruction. Microsurgery. 2022;42:209–16. https://doi.org/10.1002/micr.30848. · DOI
  59. McGoldrick DM, Yassin Alsabbagh A, Shaikh M, Pettit L, Bhatia SK. Masseter muscle defined sarcopenia and survival in head and neck cancer patients. Br J Oral Maxillofac Surg. 2022;60:454–8. https://doi.org/10.1016/j.bjoms.2021.07.020. · DOI
  60. Morse R, Ganju RG, Gan GN, Cao Y, Neupane P, Kakarala K, et al. Sarcopenia and treatment toxicity in older adults undergoing chemoradiation for head and neck cancer: identifying factors to predict frailty. Int J Radiat Oncol. 2022;114:e295. https://doi.org/10.3390/cancers14092094. · DOI
  61. Nagpal P, Pruthi DS, Pandey M, Yadav A, Singh H. Impact of sarcopenia in locally advanced head and neck cancer treated with chemoradiation: an Indian tertiary care hospital experience. Oral Oncol. 2021;121:105483. https://doi.org/10.1016/j.oraloncology.2021.105483. · DOI
  62. Nishikawa D, Hanai N, Suzuki H, Koide Y, Beppu S, Hasegawa Y. The impact of skeletal muscle depletion on head and neck squamous cell carcinoma. ORL. 2018;80:1–9. https://doi.org/10.1159/000485515. · DOI
  63. Pai PC, Chuang CC, Chuang WC, Tsang NM, Tseng CK, Chen KH, et al. Pretreatment subcutaneous adipose tissue predicts the outcomes of patients with head and neck cancer receiving definitive radiation and chemoradiation in Taiwan. Cancer Med. 2018;7:1630–41. https://doi.org/10.1002/cam4.1365. · DOI
  64. Van Rijn-Dekker MI, Van Den Bosch L, Van Den Hoek JGM, Bijl HP, Van Aken ESM, Van Der Hoorn A, et al. Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy. Radiother Oncol. 2020;147:103–10. https://doi.org/10.1016/j.radonc.2020.03.014. · DOI
  65. Shodo R, Yamazaki K, Ueki Y, Takahashi T, Horii A. Sarcopenia predicts a poor treatment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy. Eur Arch Otorhinolaryngol. 2021;278:2001–9. https://doi.org/10.1007/s00405-020-06273-4. · DOI
  66. Stone L, Olson B, Mowery A, Krasnow S, Jiang A, Li R, et al. Association between sarcopenia and mortality in patients undergoing surgical excision of head and neck cancer. JAMA Otolaryngol Neck Surg. 2019;145:647. https://doi.org/10.1001/jamaoto.2019.1185. · DOI
  67. Takenaka Y, Takemoto N, Otsuka T, Nishio M, Tanida M, Fujii T, et al. Predictive significance of body composition indices in patients with head and neck squamous cell carcinoma treated with nivolumab: a multicenter retrospective study. Oral Oncol. 2022;132:106018. https://doi.org/10.1016/j.oraloncology.2022.106018. · DOI
  68. Tamaki A, Manzoor NF, Babajanian E, Ascha M, Rezaee R, Zender CA. Clinical significance of sarcopenia among patients with advanced oropharyngeal cancer. Otolaryngol Neck Surg. 2019;160:480–7. https://doi.org/10.1177/0194599818793857. · DOI
  69. Thureau S, Lebret L, Lequesne J, Cabourg M, Dandoy S, Gouley C, et al. Prospective evaluation of sarcopenia in head and neck cancer patients treated with radiotherapy or radiochemotherapy. Cancers. 2021;13:753. https://doi.org/10.3390/cancers13040753. · DOI
  70. Van Heusden HC, Chargi N, Dankbaar JW, Smid EJ, De Bree R. Masseter muscle parameters can function as an alternative for skeletal muscle mass assessments on cross-sectional imaging at lumbar or cervical vertebral levels. Quant Imaging Med Surg. 2022;12:15–27. https://doi.org/10.21037/qims-21-43. · DOI · Paper page
  71. Wendrich AW, Swartz JE, Bril SI, Wegner I, De Graeff A, Smid EJ, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol. 2017;71:26–33. https://doi.org/10.1016/j.oraloncology.2017.05.012. · DOI · Paper page
  72. Willemsen ACH, De Moor N, Van Dessel J, Baijens LWJ, Bila M, Hauben E, et al. The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients. Cancer Med. 2023;12:7699–712. https://doi.org/10.1002/cam4.5522. · DOI
  73. Xing X, Zhou X, Yang Y, Li Y, Hu C, Shen C. The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy. Ann Transl Med. 2021;9:1180–1180. https://doi.org/10.21037/atm-21-3412. · DOI
  74. Yamahara K, Mizukoshi A, Lee K, Ikegami S. Sarcopenia with inflammation as a predictor of survival in patients with head and neck cancer. Auris Nasus Larynx. 2021;48:1013–22. https://doi.org/10.1016/j.anl.2021.03.021. · DOI
  75. Yoshimura T, Suzuki H, Takayama H, Higashi S, Hirano Y, Tezuka M, et al. Impact of preoperative low prognostic nutritional index and high intramuscular adipose tissue content on outcomes of patients with oral squamous cell carcinoma. Cancers. 2020;12:3167. https://doi.org/10.3390/cancers12113167. · DOI
  76. Yunaiyama D, Okubo M, Arizono E, Tsukahara K, Tanigawa M, Nagao T, et al. Sarcopenia at the infrahyoid level as a prognostic factor in patients with advanced-stage non-virus-related head and neck carcinoma. Eur Arch Otorhinolaryngol. 2022;279:3131–7. https://doi.org/10.1007/s00405-021-07147-z. · doi:10.1007/s00405-021-07147-z
  77. Swartz JE, Pothen AJ, Wegner I, Smid EJ, Swart KMA, De Bree R, et al. Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol. 2016;62:28–33. https://doi.org/10.1016/j.oraloncology.2016.09.006. · DOI · Paper page
  78. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. J Lab Clin Med. 2001;137:231–43. https://doi.org/10.1067/mlc.2001.113504. · DOI · Paper page
  79. Cole CL, Kleckner IR, Jatoi A, Schwarz EM, Dunne RF. The role of systemic inflammation in cancer‐associated muscle wasting and rationale for exercise as a therapeutic intervention. JCSM Clin Rep. 2018;3:1–19. · DOI
  80. Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer. 2008;16:447–51. https://doi.org/10.1007/s00520-007-0388-7. · DOI
  81. Capitão C, Coutinho D, Neves PM, Capelas ML, Pimenta NM, Santos T, et al. Protein intake and muscle mass maintenance in patients with cancer types with high prevalence of sarcopenia: a systematic review. Support Care Cancer. 2022;30:3007–15. https://doi.org/10.1007/s00520-021-06633-8. · DOI
  82. the PreMiO Study Group, Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saracino V, et al. Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. Oncotarget. 2017;8:79884–96. https://doi.org/10.18632/oncotarget.20168. · DOI · Paper page
  83. Petermann‐Rocha F, Balntzi V, Gray SR, Lara J, Ho FK, Pell JP, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta‐analysis. J Cachexia Sarcopenia Muscle. 2022;13:86–99. https://doi.org/10.1002/jcsm.12783. · DOI · Paper page
  84. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67. https://doi.org/10.1016/j.ejca.2015.12.030. · DOI · Paper page
  85. Rier HN, Jager A, Sleijfer S, Maier AB, Levin MD. The prevalence and prognostic value of low muscle mass in cancer patients: a review of the literature. Oncologist. 2016;21:1396–409. https://doi.org/10.1634/theoncologist.2016-0066. · DOI · Paper page
  86. Van Heusden HC, Swartz JE, Chargi N, De Jong PA, Van Baal MCPM, Wegner I, et al. Feasibility of assessment of skeletal muscle mass on a single cross-sectional image at the level of the fourth thoracic vertebra. Eur J Radio. 2021;142:109879. https://doi.org/10.1016/j.ejrad.2021.109879. · DOI
  87. Zwart AT, Cavalheiro VJ, Lamers MJ, Dierckx RAJO, De Bock GH, Halmos GB, et al. The validation of low-dose CT scans from the [18F]-FDG PET-CT scan to assess skeletal muscle mass in comparison with diagnostic neck CT scans. Eur J Nucl Med Mol Imaging. 2023;50:1735–42. https://doi.org/10.1007/s00330-020-07440-1. · DOI
  88. Zwart AT, Becker JN, Lamers MJ, Dierckx RAJO, De Bock GH, Halmos GB, et al. Skeletal muscle mass and sarcopenia can be determined with 1.5-T and 3-T neck MRI scans, in the event that no neck CT scan is performed. Eur Radio. 2021;31:4053–62. https://doi.org/10.1007/s00259-023-06117-3. · DOI
  89. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–35. https://doi.org/10.1016/s1470-2045(08)70153-0. · DOI · Paper page
  90. Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–47. https://doi.org/10.1200/jco.2012.45.2722. · DOI · Paper page
  91. Ye Z, Saraf A, Ravipati Y, Hoebers F, Catalano PJ, Zha Y, et al. Development and validation of an automated image-based deep learning platform for sarcopenia assessment in head and neck cancer. JAMA Netw Open. 2023;6:e2328280. https://doi.org/10.1001/jamanetworkopen.2023.28280. · DOI
  92. Naser MA, Wahid KA, Grossberg AJ, Olson B, Jain R, El-Habashy D, et al. Deep learning auto-segmentation of cervical skeletal muscle for sarcopenia analysis in patients with head and neck cancer. Front Oncol. 2022;12:930432. https://doi.org/10.3389/fonc.2022.930432. · DOI
  93. Hua X, Liu S, Liao JF, Wen W, Long ZQ, Lu ZJ, et al. When the loss costs too much: a systematic review and meta-analysis of sarcopenia in head and neck cancer. Front Oncol. 2020;9:1561. https://doi.org/10.3389/fonc.2019.01561. · DOI
  94. Findlay M, White K, Lai M, Luo D, Bauer JD. The association between computed tomography–defined sarcopenia and outcomes in adult patients undergoing radiotherapy of curative intent for head and neck cancer: a systematic review. J Acad Nutr Diet. 2020;120:1330–.e8. https://doi.org/10.1016/j.jand.2020.03.021. · DOI
  95. Findlay M, White K, Stapleton N, Bauer J. Is sarcopenia a predictor of prognosis for patients undergoing radiotherapy for head and neck cancer? A meta-analysis. Clin Nutr. 2021;40:1711–8. https://doi.org/10.1016/j.clnu.2020.09.017. · DOI
  96. Takenaka Y, Takemoto N, Oya R, Inohara H. Prognostic impact of sarcopenia in patients with head and neck cancer treated with surgery or radiation: a meta-analysis. PLOS ONE. 2021;16:e0259288. https://doi.org/10.1371/journal.pone.0259288. Birkeland A, editor · DOI
  97. Wong A, Zhu D, Kraus D, Tham T. Radiologically defined sarcopenia affects survival in head and neck cancer: a meta‐analysis. Laryngoscope. 2021;131:333–41. https://doi.org/10.1002/lary.28616. · DOI
  98. Surov A, Wienke A. Low skeletal muscle mass predicts relevant clinical outcomes in head and neck squamous cell carcinoma. A meta analysis. Ther Adv Med Oncol. 2021;13:175883592110088. https://doi.org/10.1177/17588359211008844. · DOI
  99. Edwards A, Hughes BGM, Brown T, Bauer J. Prevalence and impact of computed tomography–defined sarcopenia on survival in patients with human papillomavirus–positive oropharyngeal cancer: a systematic review. Adv Nutr. 2022;13:2433–44. https://doi.org/10.1093/advances/nmac076. · DOI
  100. Graves JP, Daher GS, Bauman MMJ, Moore EJ, Tasche KK, Price DL, et al. Association of sarcopenia with oncologic outcomes of primary treatment among patients with oral cavity cancer: a systematic review and meta-analysis. Oral Oncol. 2023;147:106608. https://doi.org/10.1016/j.oraloncology.2023.106608. · DOI

Metadata

Authors
van Heusden, H. C., van Beers, M. A., Schaeffers, A. W. M. A., Swartz, E., Swartz, J. E., & de Bree, R.
Venue
British Journal of Cancer
Published
2025-06-02
Volume
133
Issue
2
Pages
131-143
ISSN
  • 0007-0920
  • 1532-1827
Cited by
25
References
9
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The predictive and prognostic role of radiologically defined sarcopenia in head and neck cancer: a systematic review and multi-level meta-analysis. https://app.cochat.ai/papers/10.1038/s41416-025-03049-7
The paper
van Heusden, H. C., van Beers, M. A., Schaeffers, A. W. M. A., Swartz, E., Swartz, J. E., & de Bree, R. (2025). The predictive and prognostic role of radiologically defined sarcopenia in head and neck cancer: a systematic review and multi-level meta-analysis. British Journal of Cancer. https://doi.org/10.1038/s41416-025-03049-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.